Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Agios Pharmaceuticals has released an update on its Phase 2 trial of tebapivat, a potential therapy for sickle cell disease. The announcement underscores ongoing efforts to address this rare disease and bring new options to those affected.
1 day ago
1 min read